NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025
Rhea-AI Summary
NeuroPace (NASDAQ: NPCE), a medical device company specializing in epilepsy treatment, has scheduled its second quarter 2025 financial results announcement for August 12, 2025 after market close.
The company will host a conference call at 1:30 PM PT / 4:30 PM ET on the same day. Investors can join via webcast or telephone, with the webcast being archived on NeuroPace's investor relations website for at least 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – NPCE
In the trading session that priced this news, NPCE declined 0.23%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the second quarter of 2025 after market close on Tuesday, August 12, 2025. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
Investors interested in listening to the conference call may do so by accessing a live webcast of the event at https://viavid.webcasts.com/starthere.jsp?ei=1724652&tp_key=858d589533. Individuals interested in participating in the call via telephone may access the call by dialing +1-877-407-3982 and referencing Conference ID 13754370. The webcast will be archived on the company’s investor relations website at https://investors.neuropace.com/news-and-events/events and will be available for replay for at least 90 days after the event.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Investor Contact:
Scott Schaper
Head of Investor Relations
sschaper@neuropace.com
